ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

INJECTION

ADVANCING SUBCUTANEOUS INFUSION THERAPY FOR PATIENTS THROUGH INNOVATION AND PARTNERSHIPS

Julien Vandewalle and Clare Holden explain Convatec’s long-term partnerships with pharmaceutical and medical device companies are driving development in chronic care by introducing subcutaneous technologies that support the treatment of conditions such as diabetes and Parkinson’s disease – showcasing Convatec’s Neria™ Guard infusion set.

Interview: Understanding the Impact of USP<382> on Primary Packaging Development

Laure-Hélène Guillemot discusses the new USP <382> chapter coming into force on December 1st, 2025, which will significantly transform functional testing protocols for pharmaceutical companies.

NEXT-GENERATION SURFACE TECHNOLOGIES FOR MEDICAL INJECTION MOULDING

Rob Doorakkers of IGS GeboJagema, and Stephan Plassmann of Gloss & Coating, discuss their new Translatio-Coating technology for treating the surfaces of steel parts to achieve microscopic levels of optimisation and open new possibilities for efficiency and quality in drug delivery device manufacturing.

RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES

RETHINKING GLP-1 DELIVERY DEVICES: DESIGNING FOR USERS BEYOND DIABETES

Dan Lock explores how the experiences and motivations of individuals using glucagon-like peptide 1 drugs for weight loss may differ from those managing diabetes or heart disease.

THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS

Mary Lou Glotzbach

Grand River Aseptic Manufacturing

THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS

Mary Lou Glotzbach and Dr Greg Moakes consider the implications of the increasing demand for high-volume injections across the drug delivery industry, and how technologies such as wearable injectors are creating novel challenges for the fill-finish process due to the novel containers involved, making the case that it is only through clear communication and close collaboration between partners that these challenges can be met and surmounted.

PROTECTION AND PRODUCTION: OPTIMISING PRIMARY PACKAGING SOLUTIONS FOR mRNA THERAPIES

Enrico Barichello

Stevanato Group

PROTECTION AND PRODUCTION: OPTIMISING PRIMARY PACKAGING SOLUTIONS FOR mRNA THERAPIES

Enrico Barichello and Riccardo Prete discuss the impact that mRNA-based therapies are having on the modern pharmaceutical market and how these delicate therapies require careful handling, with a particular focus on how Stevanato’s portfolio of primary packaging products can be highly beneficial when bringing these critical medicines to market.

VYTAL – ONE STEP INTO THE FUTURE OF CONTAINER-CLOSURE SYSTEMS

Ana Isabel Gutierrez

VYTAL – ONE STEP INTO THE FUTURE OF CONTAINER-CLOSURE SYSTEMS

Ana Isabel Gutierrez looks at advancements in sterile and aseptic filling methods in the pharmaceutical industry, introducing H&T Presspart's Vytal® snap-fit container-closure system, which is designed to meet the growing regulatory demands of the pharmaceutical industry.

GREATER FORMULATION FREEDOM WITH A NOVEL AUTOINJECTOR PLATFORM THAT EXTENDS VOLUME AND VISCOSITY LIMITS

Prof Sigrid Saaler-Reinhardt

GREATER FORMULATION FREEDOM WITH A NOVEL AUTOINJECTOR PLATFORM THAT EXTENDS VOLUME AND VISCOSITY LIMITS

Prof Sigrid Saaler-Reinhardt, Dr Andrea Lennerz, Moritz Mond and Marie Stockton discuss how the Gx Inbeneo^® autoinjector overcomes the limitations of prefilled syringe-based autoinjectors to provide effective, safe administration of large-volume, high-viscosity formulations.

YES, PEN INJECTORS CAN ACCOMMODATE MORE THAN JUST INSULIN

YES, PEN INJECTORS CAN ACCOMMODATE MORE THAN JUST INSULIN

Cécile Gross and Mark Tunkel explore the benefits of pen injectors, highlighting their versatility and ease of use, and introduce Nemera’s novel platforms and how they can be adapted for a wide range of indications, enhancing treatment options and the patient experience.

TRANSFORMING PARENTERAL DELIVERY: KEY CONSIDERATIONS FOR SC AND IM FORMULATION DEVELOPMENT

PCI Pharma Services

TRANSFORMING PARENTERAL DELIVERY: KEY CONSIDERATIONS FOR SC AND IM FORMULATION DEVELOPMENT

Jeff Clement of PCI looks at the changing landscape of parenteral delivery, considering the pros and cons of intravenous, subcutaneous and intramuscular formulations and considers how new technologies are reshaping the drug delivery landscape.

Product Showcase: CCBIO’S INJECTOR PLATFORM PRODUCTS

Product Showcase: CCBIO’S INJECTOR PLATFORM PRODUCTS

CCBio’s expanding portfolio of self-injection devices reflects the growing importance of at-home administration in driving adherence across a range of therapies. This showcase explores the clinical rationale behind self-injection and details CCBio’s latest innovations, including electronic-assisted devices and Taiwan-based automated assembly.

DRIVING SUSTAINABILITY IN DRUG DELIVERY DEVICE DESIGN AND MANUFACTURING

Martin Høier Thomsen

DRIVING SUSTAINABILITY IN DRUG DELIVERY DEVICE DESIGN AND MANUFACTURING

Martin Høier Thomsen discusses the need for the pharma industry to rise to the challenges of meeting its sustainability goals, explaining how MGS’ expertise and established practices to drug delivery device design and manufacture present a forward-thinking approach to achieving this aim.

Interview: PDA Miniverse and Trends in Injectable Drug Delivery

Mathias Romacker

Interview: PDA Miniverse and Trends in Injectable Drug Delivery

In this exclusive interview, Mathias Romacker and Evan Edwards talk with ONdrugDelivery’s Guy Furness about the upcoming inaugural PDA Miniverse conference in Indianapolis, and the topics and trends currently being felt across the injectable drug delivery industry.

OPTIMISING HIGH-DOSE DELIVERY: SYRINGE-AUTOINJECTOR INTEGRATION, INJECTION TIME AND PERFORMANCE

OPTIMISING HIGH-DOSE DELIVERY: SYRINGE-AUTOINJECTOR INTEGRATION, INJECTION TIME AND PERFORMANCE

Thomas Blaser and Dr Maëlle Douaire explore how drug viscosity, autoinjectors and syringes affect the administration of injectable therapies, demonstrating the results of a study evaluating combined autoinjectors and syringes from the two companies that provide efficient and smooth delivery of high-dose therapies.

CRITICAL LESSONS LEARNED: STRATEGIC PLANNING FOR DRUG DELIVERY SYSTEMS

INDUSTRIALISATION

Dr Steve Badelt

BlueRidge Life Sciences

CRITICAL LESSONS LEARNED: STRATEGIC PLANNING FOR DRUG DELIVERY SYSTEMS

Dr Steve Badelt of Suttons Creek, a BlueRidge Life Sciences company, discusses how the differing cultures and mindsets common to drug development and device design need to be brought together to achieve a smooth and successful combination product development programme, and explores some best practices for achieving optimal outcomes.

SAE’s Injectable Drug Delivery 2025 – Driving Innovation Through Collaboration

CONFERENCE SHOWCASE

SAE’s Injectable Drug Delivery 2025 – Driving Innovation Through Collaboration

Projected to reach US$1,139 billion (£852 billion) by 2029, the injectable drug delivery market is rapidly growing—but what’s driving this evolution? From complex biologics and increased demand for patient self-administration to advanced delivery technologies, the answers will be centre stage at this year’s Injectable Drug Delivery Conference.

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

Dr Patrick Anquetil

Portal Instruments

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

In this exclusive interview with ONdrugDelivery’s Guy Furness, Dr Patrick Anquetil offers insight into the extensive waste involved in the self-injection market. He explains how pivoting from a model focused on fully disposable devices to reusable electromechanical autoinjectors could offer a more sustainable and cost-effective path forward.

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin Van der Heul

ALBIS Distribution

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin van der Heul considers the increasing regulatory pressure on manufacturers to deliver sustainable solutions in the medical device industry. This article explores these innovations and their impact on the future of drug delivery devices.

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

PCI Pharma Services

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

Ann Cartwright and Tim Hansen explain the five key components of PCI's sustainable procurement strategy to increase efficiency, meet regulatory demands and support business resilience and sustainability in the long term.

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group examines how semi-reusable, modular designs like its Vertiva 10 mL on-body delivery system can reconcile patient demands for ease of use with growing expectations for sustainability, sharing new UK preference data and lifecycle analysis that reveal significant waste and emissions reductions.

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

Lorenzo Biasio and Gloria Skibba discuss the integration of Ypsomed’s Net Zero Program into its self-injection platforms. With the evolution of GLP-1 therapies and the exploration of higher-dose formulations, the demand for higher-volume autoinjectors is increasing; this article explains how Ypsomed has also applied its sustainability principles to larger-volume delivery.

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

Jack Eaton considers the current landscape for drug delivery and packaging, and how developments and research in nonwoven and fibrous materials can help businesses address the problem of per- and polyfluoroalkyl substances.

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

Sas Maheswaran discusses how artificial intelligence, data and strategic partnerships can make clinical trials more sustainable – both financially and environmentally.

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

Julian Lotz introduces bio-based solutions for drug delivery devices, excelling in quality while meeting upcoming sustainability regulations, and explores the future of bioplastics in the healthcare sector.

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

Luca Chiochia discusses the vital role of coloured plastics in medical devices and how the use of pre-coloured, pre-tested solutions can provide not only a significantly reduced regulatory burden for device developers and manufacturers but also a higher quality end product, going on to explain how the company is approaching the critical subject of producing more sustainable polymers.

THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS

Jonathan Mulpas

THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS

Jonathan Mulpas discusses how advanced inhaled drug delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential and the expertise that Aptar can offer in this area.

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Dr Heather Jameson

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.

1
2
3
…
64
Next

See what ondrugdelivery's readers and contributors think

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Top